Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1217 of 5804
-
Experimental cell therapy takes on lupus and other autoimmune diseases
Disease control Recruiting nowThis study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and SLE-ITP, Sjogren's Syndrome, etc. Aproximately 18 patients aged 18-65 will receive a single infusion o…
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New IVIg therapy aims to boost platelets in chronic ITP patients
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of KIg 10 (Intravenous Immunoglobulin 10%) in adult patients with chronic primary ITP
Phase: PHASE3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Could a simple Self-Swab replace the pap smear? indonesia tests HPV Self-Collection
Diagnosis ENROLLING_BY_INVITATIONThe purpose of this study is to implement human papillomavirus (HPV) self-collection in Indonesia.
Phase: NA • Sponsor: Dharmais National Cancer Center Hospital • Aim: Diagnosis
Last updated Jun 26, 2026 18:07 UTC
-
Experimental cocktail aims to outsmart Hard-to-Treat breast cancer
Disease control Recruiting nowThe goal of this clinical research study is to find the best dose of the drugs cyclophosphamide and axatilimab that can be given in combination with the standard dose of retifanlimab to patients with metastatic TNBC.
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for indian patients with psoriatic arthritis: guselkumab trial launches
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and how well guselkumab treatment works (efficacy) in participants with psoriatic arthritis (PsA; a chronic, autoimmune form of arthritis that causes joint inflammation) who had inadequate response to standard therapies.
Phase: PHASE4 • Sponsor: Johnson & Johnson Private Limited • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
BioNTech launches trial of BNT326 for advanced cancers
Disease control Recruiting nowThis study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanc…
Phase: PHASE1, PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New implant aims to stop sleep apnea episodes
Disease control Recruiting nowThe objectives of this study are to evaluate the feasibility of the remedē® Dual Channel System at implant and overnight sleep studies and to assess chronic safety.
Phase: NA • Sponsor: Zoll Medical Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug aims to reduce Blood-Letting in rare blood cancer
Disease control Recruiting nowThis open-label, multicenter, within-participant dose escalation study examining up to 2 dose levels of DISC-3405 will assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of DISC-3405 in participants with polycythemia vera (PV).
Phase: PHASE2 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New shot aims to tame COPD Flare-Ups in inflammatory subtype
Disease control OngoingThis is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation
Phase: PHASE2 • Sponsor: Connect Biopharm LLC • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New sleep disorder drug ORX750 tested for Long-Term safety
Disease control Recruiting nowThis study is a long-term extension (LTE) of the parent Study ORX750 0201, and will provide long-term open-label safety, tolerability, and efficacy of ORX750 in participants with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).
Phase: PHASE2 • Sponsor: Centessa Pharmaceuticals (UK) Limited • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Robot trainer aims to get stroke patients back on their feet
Symptom relief Recruiting nowWalking rehabilitation after stroke is most effective during the first three months of recovery, but even in the chronic phase-beyond six months post-stroke-a significant number of patients still show potential for gait improvement. Robot-assisted rehabilitation is becoming incre…
Phase: NA • Sponsor: National Taiwan University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Can a smartphone app lift depression in cancer survivors?
Symptom relief Recruiting nowThe purpose of this research study is to evaluate different depression treatment approaches among cancer survivors. A cancer survivor is defined as anyone who is living and has been diagnosed with cancer. Participants will be randomly assigned to either receive a mobile app for …
Phase: NA • Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Jul 16, 2026 00:00 UTC
-
New drug RC278 targets Hard-to-Treat solid tumors in early trial
Disease control Recruiting nowThe primary objective is to evaluate the safety and tolerability of RC278; determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of RC278; and determine the recommended phase 2 dose (RP2D), and assess the efficacy of RC278 at the RP2D dose;
Phase: PHASE1, PHASE2 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Silent spreaders? study probes asymptomatic TB transmission
Knowledge-focused Recruiting nowTuberculosis (TB) remains one of the world's leading causes of morbidity and mortality. Current TB control strategies focus largely on the binary paradigm of TB, which tackle Mtb infection and the symptomatic stages of the disease as the major drivers of the TB epidemic. However,…
Sponsor: Barcelona Institute for Global Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
High-Fat diet may stop infant seizures before they start
Prevention Recruiting nowEpileptic spasms (ES) are a predominantly infantile seizure type observed frequently in certain genetic disorders. Ketogenic diet (high ratio of fat to carbohydrate/protein) is an established non-medication treatment for difficult to control seizures, including ES. Because ES are…
Phase: PHASE1 • Sponsor: Heather Olson • Aim: Prevention
Last updated Jul 08, 2026 00:00 UTC
-
New PKU drug JNT-517 moves to Long-Term safety trial
Disease control Recruiting nowThe goal of this Phase 3, open-label study is to evaluate the long-term safety of JNT-517 in pediatric and adult participants with Phenylketonuria (PKU) after completion of either Study JNT517-101 (NCT05781399) or JNT517-201 (NCT06637514) as well as participants who have not part…
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New Real-World study tests nemolizumab for chronic itch condition
Symptom relief Recruiting nowThe main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outcome (PRO) in clinical practice at Month 6.
Sponsor: Galderma R&D • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New drug aims to cool inflammation in heart arteries after attack
Disease control Recruiting nowThe goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is: Clinical effects of or…
Phase: PHASE2 • Sponsor: Abcentra • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New study tracks Efgartigimod's Real-World impact on CIDP patients
Disease control Recruiting nowThe aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), describe the "treatment journey" of participants with CIDP, and assess the utilization of health care services among adu…
Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New therapy targets shame to save teen lives
Symptom relief Recruiting nowThis pilot randomized controlled trial (RCT) aims to evaluate the feasibility, acceptability, and preliminary efficacy of Shame-Focused Cognitive Behavioral Therapy (SF-CBT) among high-risk psychiatric inpatient adolescents. Shame has been identified as a critical psychological m…
Phase: NA • Sponsor: Peking University • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC